8-K: Oragenics Regains NYSE Compliance, Secures Capital

Oragenics, Inc. announced it has regained full compliance with NYSE American listing standards and secured significant capital to advance its lead clinical program.

Summary

• Oragenics, Inc. (OGEN) has regained full compliance with NYSE American continued listing standards, effective October 20, 2025, with the .BC indicator to be removed on October 21, 2025.
• The company previously received deficiency letters from NYSE American on April 16, 2024, and August 13, 2024, for not meeting stockholders' equity requirements (Sections 1003(a)(i), (ii), and (iii)).
• A plan of compliance was submitted on May 17, 2024, and accepted by NYSE American on June 18, 2024.
• Oragenics settled all claims with Ladenburg Thalmann & Co., Inc. for $700,000 on October 16, 2025, resolving a dispute over a $2,500,000 fee related to an asset purchase from Odyssey Health, Inc.
• The company successfully completed a public offering of Series H Convertible Preferred Stock on July 2, 2025, generating gross proceeds of approximately $16.5 million.
• Prior to that, Oragenics sold 7.8 million shares of Common Stock via its ATM program on February 5, 2025, for gross proceeds of $2.75 million.
• On September 5, 2024, the company completed a public offering of Common Stock and Pre-Funded Warrants, resulting in gross proceeds of approximately $4.45 million.
• As a result of these efforts, the company's stockholders' equity now exceeds $6.0 million as of October 18, 2025, bringing it into compliance with NYSE American standards.
• With compliance restored and capital secured, Oragenics is now singularly focused on advancing ONP-002, its lead candidate for concussion and mild traumatic brain injury, through Phase IIa clinical trials in Australia and planned U.S. Phase IIb trials.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the successful resolution of significant financial and regulatory challenges (NYSE compliance, capital raises, legal settlement) which de-risk the company's operational stability and provide a clear path forward for its lead clinical program. This represents a major turnaround from a precarious position.

Positives

• Regained full compliance with NYSE American listing standards, removing the threat of delisting and the .BC indicator.
• Successfully raised approximately $16.5 million in gross proceeds from a public offering of Series H Convertible Preferred Stock in July 2025, significantly strengthening the balance sheet.
• Secured additional capital through an ATM program ($2.75 million gross proceeds in February 2025) and another public offering ($4.45 million gross proceeds in September 2024).
• Resolved a legal dispute with Ladenburg Thalmann & Co., Inc. for $700,000, significantly less than the $2,500,000 claimed.
• Stockholders' equity now exceeds $6.0 million, surpassing the NYSE American requirement.
• The company is now singularly focused on advancing its lead clinical program, ONP-002, for concussion and mild traumatic brain injury, providing a clear strategic direction and clinical runway.

Negatives

• Paid $700,000 to Ladenburg Thalmann & Co., Inc. to settle a dispute, which represents a cash outflow.
• The company previously faced delisting procedures due to sustained losses and insufficient stockholders' equity over multiple fiscal years.

Risks

• Risks related to the clinical development process of ONP-002, including potential delays, failures, or unexpected results in trials.
• Risks associated with regulatory approval processes for new drug candidates.
• The company's ability to secure adequate funding for future operations and clinical trials beyond the current runway.
• General risks set forth in Oragenics' most recent Forms 10-K, 10-Q, and other SEC filings.

Future Outlook

Oragenics is now singularly focused on advancing ONP-002, its lead candidate for concussion and mild traumatic brain injury. The company is progressing Phase IIa clinical trials in Australia, with U.S. Phase IIb trials planned to follow. The capital raised provides a meaningful runway to achieve critical Phase II clinical milestones.

Management Comments

• "Regaining compliance represents more than a regulatory milestone—it reflects our commitment to transparency, financial discipline, and restoring investor confidence."
• "We acknowledged the equity deficiency directly, took decisive action to address it, and emerged with a strengthened balance sheet that supports our clinical objectives."
• "We’ve cleaned house financially and operationally. Our team is fully aligned on one objective: delivering clinical data that validates ONP-002’s potential to transform care for patients suffering from traumatic brain injuries. That’s where our energy and capital are now directed."

Industry Context

Oragenics operates in the clinical-stage biotechnology sector, specifically focusing on brain-targeted therapeutics using proprietary intranasal delivery technology. The development of ONP-002 for concussion and mild traumatic brain injury addresses a significant unmet medical need, as there are currently limited effective treatments for these conditions. Success in this area could position Oragenics as a leader in neurological therapeutics, leveraging its unique delivery platform which has broad potential applications.

Corporate Governance

Legal Proceedings

• Settlement Agreement entered into with Ladenburg Thalmann & Co., Inc. on October 16, 2025, resolving all claims, including those arising under the Investment Banking Agreement dated December 7, 2022. Oragenics paid $700,000 in exchange for a mutual release of claims, dismissing the confidential arbitration action initiated by Oragenics on March 12, 2024.

Stakeholder Impact

• **Shareholders:** Benefit from the removal of delisting risk, strengthened balance sheet, and clear strategic focus on the lead clinical asset. The capital raises dilute existing shareholders but provide necessary funding.
• **Employees:** Benefit from increased job security and a clearer strategic direction for the company.
• **Creditors:** Benefit from a strengthened financial position and improved ability to meet obligations.
• **Patients:** Potential future benefit from the advancement of ONP-002 as a treatment for concussion and mild traumatic brain injury.

Next Steps

• Advance ONP-002 through Phase IIa clinical trials in Australia.
• Prepare for U.S. Phase IIb trials for ONP-002.
• Continue to execute on the strategic focus of delivering clinical data for ONP-002.

Key Dates

Recommendation

The company has successfully addressed critical financial and regulatory hurdles, including regaining NYSE American compliance and securing substantial capital. This significantly de-risks the operational stability of a clinical-stage biotechnology company. With a strengthened balance sheet and a clear focus on advancing its lead candidate, ONP-002, into further clinical trials, the company is now better positioned to pursue its strategic objectives. While clinical trial risks remain inherent, the resolution of these foundational issues presents a compelling entry point for investors willing to take on the remaining development risks, as the company-specific financial overhang has been largely removed.

Keywords

Oragenics, OGEN, NYSE American, Listing Compliance, Stockholders Equity, Capital Raise, Public Offering, Series H Preferred Stock, ONP-002, Concussion, Mild Traumatic Brain Injury, Biotechnology, Clinical Trials, Intranasal Delivery, SEC Filing, 8-K, Ladenburg Thalmann, Settlement Agreement